The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL).
Hun Ju Lee
No relevant relationships to disclose
William G. Wierda
No relevant relationships to disclose
Alessandra Ferrajoli
No relevant relationships to disclose
Jan Andreas Burger
No relevant relationships to disclose
Long Trinh
No relevant relationships to disclose
Susan Lerner
No relevant relationships to disclose
Michael J. Keating
No relevant relationships to disclose
Susan Mary O'Brien
Research Funding - Genentech